uuid:
  -
    value: 9027674d-7887-4a3e-9175-6faeabc15473
langcode:
  -
    value: und
type:
  -
    target_id: case_series
    target_type: node_type
    target_uuid: 0ea0fe3a-e616-4d45-88b7-f6bb126fd852
revision_timestamp:
  -
    value: '2016-07-27T22:25:25+00:00'
    format: 'Y-m-d\TH:i:sP'
revision_uid:
  -
    target_type: user
    target_uuid: 7f2b027c-635a-47bd-9500-94902c2d3670
revision_log: {  }
status:
  -
    value: true
uid:
  -
    target_type: user
    target_uuid: 7f2b027c-635a-47bd-9500-94902c2d3670
title:
  -
    value: 'Pharmacia & Upjohn''s Xalatan'
created:
  -
    value: '2016-07-27T22:25:25+00:00'
    format: 'Y-m-d\TH:i:sP'
changed:
  -
    value: '2016-07-27T22:25:25+00:00'
    format: 'Y-m-d\TH:i:sP'
promote:
  -
    value: false
sticky:
  -
    value: false
default_langcode:
  -
    value: true
revision_translation_affected:
  -
    value: true
path:
  -
    alias: /faculty-and-research/case-series/id/a06-99-0018
body:
  -
    value: '<div class="field field-name-body field-type-text-with-summary field-label-above"><div class="field-items"><div class="field-item even"><p>Pharmacia &amp; Upjohn, Inc., a global pharmaceutical company, has received FDA approval to manufacture and distribute Xalatan, a drug developed for the treatment of glaucoma. Xalatan has the potential to be an important source of revenues and profits for the company. Beta blockers, the previous treatment for glaucoma, can cause respiratory and cardiac complications in some patients. The company must decide whether to spend $50 million to construct a manufacturing facility.</p><p>&nbsp;</p></div></div></div>'
    format: basic_html
    processed: ''
    summary: ''
    summary_processed: ''
field_case_number:
  -
    value: A06-99-0018
field_case_page_length:
  -
    value: '6 pages'
field_case_series_author:
  -
    target_type: taxonomy_term
    target_uuid: 215fca72-6707-4393-83e6-fa7e2ca6bb82
field_case_series_date: {  }
field_case_series_image: {  }
field_case_series_industry:
  - {  }
field_case_series_year:
  -
    value: '1999-01-01'
field_case_setting:
  -
    value: 'United States, 1996'
field_case_source:
  -
    value: 'Field case'
field_case_subject:
  -
    target_type: taxonomy_term
    target_uuid: 5d6eba99-f8ab-4ad8-88bc-9d20e713d129
field_fields:
  -
    target_type: taxonomy_term
    target_uuid: 7a2168f5-adeb-4285-9c4b-9e990c161c67
field_teaching:
  -
    value: "The case asks participants to (a) develop projected financial statements (balance sheet, income statement, and statement of cash flows), and (b) evaluate a capital budgeting proposal using discounted cash flows analysis and a company-wide cost of capital of 13%. The case has been used in executive programs, although in this setting, the instructor should provide participants with the projections and focus the discussion on the sensitivity of the projected numbers to the assumptions imbedded in the case. The case could be used in masters-level programs where participants could be expected to develop the forecasted financial statements.\r\n\r\n"
_content_sync:
  entity_type: node
  entity_dependencies:
    user:
      - user.user.7f2b027c-635a-47bd-9500-94902c2d3670
    taxonomy_term:
      - taxonomy_term.case_series_authors.215fca72-6707-4393-83e6-fa7e2ca6bb82
      - taxonomy_term.case_series_categories.5d6eba99-f8ab-4ad8-88bc-9d20e713d129
      - taxonomy_term.case_series_fields.7a2168f5-adeb-4285-9c4b-9e990c161c67
